FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 12/01/2016 |
3. Issuer Name and Ticker or Trading Symbol
Quintiles IMS Holdings, Inc. [ Q ] |
|||||||||||||
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 12,614(1) | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Employee Stock Option (Right to Buy) | (2) | 09/16/2023 | Common Stock | 10,000 | $44.45 | D | |
Employee Stock Option (Right to Buy) | (3) | 02/25/2024 | Common Stock | 17,200 | $53.26 | D | |
Employee Stock Option (Right to Buy) | (4) | 03/04/2025 | Common Stock | 9,900 | $64.93 | D | |
Employee Stock Option (Right to Buy) | (5) | 03/03/2026 | Common Stock | 7,000 | $64.67 | D |
Explanation of Responses: |
1. This amount includes 866 RSUs granted on March 4, 2015 which will vest in three annual installments beginning on March 4, 2017, 2,319 RSUs granted on March 3, 2016 of which will vest in four annual installments beginning on March 3, 2017 and 9,252 RSUs granted on September 30, 2016 of which 3,146 vest on September 30, 2017, 3,053 vest on September 30, 2018, and 3,053 vest on September 30, 2019. |
2. This option remains outstanding under the grant; 7,500 of which are currently vested; and 2,500 of which will vest on September 16, 2017. |
3. This option remains outstanding under the grant; 8,600 of which are currently vested; and 8,600 of which will vest in two annual installments beginning on February 25, 2017. |
4. This option remains outstanding under the grant; 2,475 of which are currently vested; and 7,425 of which will vest in three annual installments beginning on March 4, 2017. |
5. This option will vest in four annual installments beginning on March 3, 2017. |
Remarks: |
4. Relationship of Reporting Person(s) to Issuer (continued): X Officer Title: President, Research & Development Solutions |
/s/ James H. Erlinger III, Attorney-in-Fact for W. Richard Staub | 12/09/2016 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |